543 Bryant Street
87 articles with ProQR Therapeutics
Dinko Valerio offers wisdom garnered from a long career as a scientist, investor and entrepreneur.
Ora®, Inc. has been retained by ProQR Therapeutics to provide mobility test services using the Ora-VNC™ for the QR-110 development program for Leber's Congenital Amaurosis Type 10
ProQR Therapeutics announced positive interim results from the Phase 1/2 Clinical Trial of QR-110, a trial managed by Ora and featuring Ora's VNC™ mobility courses
ProQR to Present Interim Phase 1/2 Results for QR-110 in Leber’s Congenital Amaurosis 10 at the Symposium for Retinal Degeneration on Sept. 5th
Presentation at the 18th International Symposium on Retinal Degeneration (RD2018) at 8:30 am GMT on Sept. 5th
Initiated WINGS, the first clinical trial to evaluate the safety and efficacy of QR-313 in patients that have recessive dystrophic epidermolysis bullosa (RDEB) due to mutations in exon 73 of the COL7A1 gene
The trial, called WINGS, will evaluate the safety and efficacy of QR-313 in subjects with recessive dystrophic epidermolysis bullosa due to mutations in exon 73 of the COL7A1 gene.
Foundation Fighting Blindness Will Provide Up to $7.5M in Funding to Develop Proqr’s Candidate QR-421a for Usher Syndrome Type 2A
Foundation Fighting Blindness and ProQR enter into a partnership to develop QR-421a for Usher syndrome type 2A, targeting mutations in exon 13 of the causative USH2A gene.
ProQR and Galapagos Announce Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer technology
The targets that will be pursued in the collaboration and financial details about the collaboration are not disclosed.
All relevant documents and information for the meeting, including the notice and agenda, are or will be made available on ProQR’s website.
ProQR Receives Orphan Drug Designation From EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa
DEB is a rare genetic disease that can lead to severe blistering of the skin resulting in high treatment burden and poor quality of life for patients.
Runway into the second half of 2019: cash of €39.7 million at end of Q3.
ProQR Prices Approximately $20M Underwritten Public Offering and Concurrent Registered Direct Offering of Ordinary Shares
In addition, in the public offering, ProQR has granted the underwriters a 30-day option to purchase up to 745,471 additional ordinary shares at the public offering price, less underwriting discounts and commissions.
ProQR expects to grant the underwriters a 30-day option to purchase additional ordinary shares, on the same terms and conditions.
ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness
The first patient has received the first dose of QR-110 in the Phase 1/2 safety & efficacy clinical trial in children and adults with Leber’s congenital amaurosis 10.
Dr. Thaddeus (Ted) Dryja is a pioneer in the field of retinal genetic diseases.
The company's CMO will leave, effective November 4, 2017 to pursue a new opportunity.
ProQR Therapeutics Presents In Vivo Proof Of Concept Data For The Axiomer RNA Editing Platform Technology
ProQR Therapeutics Receives Orphan Drug Designation From FDA For Drug Candidate QR-313 For Dystrophic Epidermolysis Bullosa And Will Present Data At Two Scientific Conferences
ProQR Therapeutics’s Drug Candidate QRX-421 For Usher Syndrome Receives Orphan Drug Designation From FDA And EMA